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ABSTRACT
Motivation: As the use of microarrays in human studies continues
to increase, stringent quality assurance is necessary to ensure
accurate experimental interpretation. We present a formal approach
for microarray quality assessment that is based on dimension
reduction of established measures of signal and noise components
of expression followed by parametric multivariate outlier testing.
Results: We applied our approach to several data resources. First,
as a negative control, we found that the Affymetrix and Illumina
contributions to MAQC data were free from outliers at a nominal
outlier ﬂagging rate of α =0.01. Second, we created a tunable
framework for artiﬁcially corrupting intensity data from the Affymetrix
Latin Square spike-in experiment to allow investigation of sensitivity
and speciﬁcity of quality assurance (QA) criteria. Third, we applied the
procedure to 507 Affymetrix microarray GeneChips processed with
RNA from human peripheral blood samples. We show that exclusion
of arrays by this approach substantially increases inferential power,
or the ability to detect differential expression, in large clinical studies.
Availability: http://bioconductor.org/packages/2.3/bioc/html/array
Mvout.html and http://bioconductor.org/packages/2.3/bioc/html/
affyContam.html affyContam (credentials: readonly/readonly)
Contact: aasare@immunetolerance.org;stvjc@channing.harvard.edu
1 INTRODUCTION
Recent successes with microarrays for the identiﬁcation of gene
patterns that correlate with disease states has resulted in their
increaseduseinhumanstudies.Asthisapproachmovesfromsmaller
scale efforts into biomarker discovery efforts in clinical trials, rapid
and reliable quality assurance approaches are necessary, both from
the perspective of ensuring accurate data for inclusion as clinical
trial secondary endpoints, and as a measure to contain costs (Group,
2004). As a large clinical trial consortium, we have processed over
1500 Affymetrix Gene Chips® from eight different clinical trials,
with these numbers growing yearly.Thus, we required a streamlined
and accurate method for deﬁning which arrays are of high quality
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and to determine the overall success rate of arrays processed in our
central laboratory.
Many of the currently used microarray quality assessments are
manufacturer-based recommendations that rely on a limited number
ofparameterswithimprecisespeciﬁcationsforacceptableresults.In
this report, we review deﬁnitions of quality assessment criteria for
Affymetrix and Illumina expression arrays, and describe algorithms
for formally identifying aberrant arrays with a speciﬁed false
positive rate. Our procedure involves parametric multivariate outlier
testing using a multivariate Gaussian model, which we apply to
principal components of the quality measure matrix.
2 METHODS
2.1 Deﬁnitions of quality metrics
For Affymetrix Gene Chips®, quality criteria include the actin (HSACO7)
and GAPDH 3 /5  ratios, the percent present calls according to the MAS5
algorithm, the array-speciﬁc scale factor and average background [see
Hubbell et al. (2002) and the Affymetrix Statistical Algorithm Reference
Guide]. The actin and GAPDH ratios indirectly reﬂect the efﬁciency of
reverse transcription of the total RNA template, as high 3  to 5  ratios
indicate poor transcription from the 3 -end, resulting in small fragments
of cDNA/cRNA available for hybridization. The other indicators reﬂect
hybridization efﬁciency as they indicate the number of probes hybridized
from the total (percent present call) and the amount of background
noise.
Bolstad et al. (2003) deﬁne probe-level modeling (PLM) for Affymetrix
arrays as a ﬂexible generalization of the established robust multiarray
preprocessing procedure (RMA) due to Irizarry et al. (2003). PLM computes
two quantities of particular interest for quality assessment. The ﬁrst, relative
log expression (RLE), examines point estimates of expression values at
the probe set level. Suppose, here and in the sequel, that there are N
arrays and G probe sets. PLM computes ˆ eij, i=1,...,G, j=1,...,N,o n
the basis of a robust regression model allowing general probe and sample
effects. The quantity ˜ ei,· is the median log expression of the i-th probe set.
RLEij=ˆ eij−˜ ei,·, computed for all probes, all arrays. Denote by RLE·j the
G-vector of RLE measures for the j-th array. Features of the distribution of
RLE·j are informative on array quality: medians should be close to zero for
all arrays, and variances should be similar across arrays. Departures from
theseconditionsareusuallyassociatedwithqualitydefects.Anotherquantity
derived from PLM is the normalized unscaled standard error (NUSE). Here,
the focus is on variability of estimation of expression. PLM computes
standard errors of all expression measures, and these are standardized, gene
by gene, across arrays, so that the median standard error across arrays is 1.
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The G-vector of NUSE for each array should have median 1 and common
variance across arrays.
Another indicator provided by the affy package of Bioconductor/R
(Gautier et al., 2004) is the RNAdegradation slope, which assesses the 3 /5 
ratio for all genes on the array. Probes are ordered within probe sets from
5 -t o3  -most and the intensity gradient along this sequence is qualitatively
estimated pointwise for each array.Arrays with quality problems can possess
aberrant gradients, typically assessed visually.
For Illumina arrays, the Bioconductor lumi package (Du et al., 2008)
includes the lumiQ function which computes a four-dimensional quality
feature vector for each array in a lumiBatch. The quality measures are
average intensity and intensity SD, average detection rate as reported by the
BeadStudio preprocessor and average Euclidean distance of probe-speciﬁc
intensities to their means over all samples.
2.2 Array quality feature-vector and dimension
reduction
For Affymetrix arrays, the metrics described above lead to nine quantitative
measures of array quality computed on each array: ABG (average
background), SF (scale factor), PP (percent present), AR (actin 3 /5 
ratio), GR (GAPDH 3 /5  ratio), median NUSE, median RLE, RLE-IQR
(interquartile range of IQR per array, to measure variability in RLE) and
RNAS (slope of RNA degradation measure). This sequence of numbers is
regarded as the array-speciﬁc quality feature vector.Aprincipal components
transformation is conducted using R function prcomp to obtain linear
combinations of the original features that are mutually orthogonal and that
capture substantial fractions of variation among samples. The use of linear
combinations also aids in procuring a multivariate representation of the
qualityinformationthatmay,underanullhypothesisofequivalentquality,be
reasonably approximated by a multivariate Gaussian probability model. We
denote by Q the N×9 feature matrix (with arrays deﬁning rows and quality
measuresdeﬁningqualities).Thematrixconsistingoftheuser-selectedm>1
initial principal components of Q as columns is denoted as P.
For Illumina arrays, we denote by Q the N×4 feature matrix of lumi-
based quality measures, to which principal components transformations may
be applied.
2.3 Multivariate outlier detection algorithms
Iftherearer >N/2non-outlyingrowsoftheN ×m matrix,P areregardedas
a collection of r samples from the m-dimensional Gaussian model Nm(µ, )
with m-dimensional mean µ and m×m covariance matrix  , an algorithm
of Caroni and Prescott (1992) can be used to identify outlying observations
among the N data rows with a ﬁxed small probability of incorrectly labeling
a non-outlying observation as an outlier.
Let S denote the m×m sample covariance matrix of the m ﬁrst principal
components of Q [taking the m columns of P as variables and the N rows
of P as observations (denoted Pi,i=1,...,N)]. Wilks’ scatter ratios are the
quantities
Wl=|S(l)|/|S|, l=1,...,N,
where S(l) denotes the sample covariance matrix of P computed with row l
removed. Wilks’ scatter ratio is the likelihood ratio test statistic of
H0:Pi∼Nm(µ, ), i=1,...,N
against
H1:Pi∼Nm(µ, ), i =j, and Pj∼Nm(µ+aj, )
where the outlier index j, the m-dimensional ‘slippage parameter’aj and the
variance parameter   are all unknown.The scatter ratio may be re-expressed
as a function of the Mahalanobis distance:
Wl=1−
N
N−1
(Pi−µ)tS−1(Pi−µ).
Caroni and Prescott implement an inward peeling followed by outward
testing procedure following a univariate procedure due to Rosner (1983).
Deﬁne D1=minj(Wj), and D2,...,DN−r as the sequence of scatter ratios
formed from successive eliminations of rows of P posessing the smallest
scatter ratios at each stage. Caroni and Prescott observe that the distribution
of Wj for given j is Beta([n−p−1]/2, p/2) and derive Bonferroni bounds
using Rosner’s arguments to obtain approximations to the distributions of
Ds, s=1,...,N−r. Critical values are obtained using these approximations
and the quantities DN−r,...,D1 are each tested at level α.I fDN−q is smaller
than the associated critical value, then the associated sample and all samples
associated with minimal scatter ratios computed at stages earlier than N −q
are declared outlying. This procedure mislabels non-outlying samples as
outliers with overall error rate α whether or not any outliers are actually
presentinP,andisimplementedinRsourcecodeinthearrayMvout package.
In tables below, we refer to the results of using this procedure as PMVO (for
Parametric MultiVariate Outlier labeling).
An important recent contribution to array outlier assessment is
the methodology of Cohen Freue et al. (2007) in which robust
Mahalanobis distances are used to identify aberrant arrays. The standard
Mahalanobis distance can be robustiﬁed by substituting for the sample
covariance a covariance estimator based on the minimum covariance
determinant,minimumvolumeellipsoidoraspeciﬁcS-estimator.Parametric
or simulation-based critical values for outlier labeling are available.
In comparative tabulations below this algorithm is denoted MDQC.
2.4 Implementation
ThearrayMvout packageincludesafunctionArrayOutliersthataccepts
an AffyBatch (imported intensity data structure derived from CEL ﬁles) or
lumiBatchinstance,speciﬁcationofα andavectorindicatingwhichprincipal
componentsaretobeusedtodeﬁneP.ArrayOutliersreturnsaninstance
of the arrOutStruct class, for which a simple reporting method is
deﬁned, showing the indices and feature values of outlying arrays; a plot
method returns the principal components biplot of Q. The object quietly
maintains results of all quality metric computations, such as the fitPLM
result, facilitating more detailed diagnosis should such be required.
2.5 Power estimation
PowerAtlas, a power and sample size estimation tool for microarray study,
was adopted to investigate impact of aberrant arrays on statistical power
for identiﬁcation of differentially expressed genes (Page et al., 2006). The
PowerAtlas tool is developed based on a mixture model approach for
estimation of power and sample size of high-dimensional data (Gadbury
et al., 2004). A list of per-gene P-values, generated from a pair-wise
comparison using LIMMA package, was used as input for PowerAtlas for
power estimation of the comparison.
3 RESULTS
3.1 Negative control: application to MAQC arrays
TheAffymetrixcontributiontotheMAQCexpressionstudyconsists
of 120 Affymetrix hgu133plus2 arrays collected from three MAQC
labs with two replicates on each of four sample types. These
arrays were produced under a strict protocol for the MAQC
cross-platform comparison (Shi et al., 2006) and so are expected
to be of very high quality. Our outlier algorithm was applied
with m=3 and α=0.01,0.05 and 0.10 with two approaches to
feature representation. As requested by two referees, we applied
outlier detection to the raw quality features without principal
components re-expression.The table entry under PMVO-raw shows
that relatively large numbers of outliers are ﬂagged with this
approach. When principal components re-expression is applied, no
outliers are detected with PMVO at α =0.01,0.05 or 0.10.
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Table 1. Application of multivariate outlier detection to negative and
positive controls derived from MAQC and Affymetrix spike-in series, the
latter with digital contamination
Negative controls
Source No. of chips No. of chips ﬂagged
PMVO-raw PVMO-PC MDQC-PC
Affy. MAQC 120 (34,34,23) (0,0,0) (9,3,1)
Illu. MAQC 19 (0,0,0) (0,0,0) (3,1,0)
Digitally contaminated arrays
Source No. of chips Contaminated Chips ﬂagged
PMVO-PC MDQC
Affy. spike-in 12 – none 2,8,10
1 1 1,8
1,2 1,2,8 1,2
1,2,11 1,2,8,11 8,10
For negative controls, table cells give number of arrays ﬂagged at α=0.10,0.05,0.01.
For positive controls, cell entries give indices of arrays contaminated or identiﬁed by
various algorithms. Method labels are: PMVO-raw, for parametric multivariate outlier
detection applied to raw QA features; PMVO-PC, for PMVO applied with dimension
reduction to ﬁrst three principal components; MDQC, for Mahalanobis distance-based
algorithm of Cohen Freue et al. (2007) with the MCD estimator of covariance, applied
to raw QC features; and MDQC-PC, for MDQC with the S-estimator of covariance
applied on PC1–PC3 of QC features.
We obtained the raw MAQC data contributions from Illumina,
Inc. (Le. Shi, personal communication), and created raw reads
of 19 arrays using the lumiR procedure of the lumi package of
Bioconductor (Du et al., 2008), and then computed the quality
measures via the lumiQ procedure. Table 1 shows that PMVO
ﬁnds no outliers, while MDQC ﬁnds a small number as long as
α≥0.05. We conclude that PMVO has reasonable speciﬁcity when
used in conjunction with principal components re-expression for
arrays produced in good quality conditions.
3.2 Sensitivity to speciﬁc contamination events
Figure 1 displays a digitally contaminated CEL ﬁle from the
Affymetrix spike-in experiment archive.The readily visible artifacts
are created by altering intensity levels in speciﬁc regions of the
chip either by ﬁxing them to constant value or by rescaling them to
achieve altered intensity variance. For conciseness, the ﬁgure shows
a chip on which four contamination events occur simultaneously; in
ourdataanalysesthesewereappliedseparatelytodifferentsubseries
of chips as shown in Table 1. The base series is the ﬁrst 12 chips
in the U133A spike-in subset. Each of four types of artifact were
introduced to chip 1, then chips 1 and 2, and then chips 1, 2 and 11,
tounderstandtheeffectsofartifacttypeandnumberonsensitivityof
outlier detection algorithms. We see that when there are no artifacts,
PMVO does not declare any array to be outlying, but MDQC (run
with default settings) declares three arrays to be outliers. Results for
PMVOandMDQCwereinvarianttothetypeofartifactwhenonly1
or 2 chips were contaminated, so contamination type is not recorded
in Table 1. When three chips were contaminated (1, 2 and 11),
Fig. 1. Composite of four types of digital contamination applied
to raw Affymetrix intensity data—the three circular subregions are,
counterclockwise from upper left, low constant, variable and high constant
blobs, and the rectangular region on the right has inﬂated variance.
PMVO always ﬂagged chips 1, 2, 8 and 11, regardless of the type
of contamination. MDQC was sensitive to type; in the table we
show that it ﬂagged chips 8 and 10, as was true for low constant
and increased variability blobs; with the high constant blob MDQC
ﬂagged 10 and 11, and for rectangle of increased variability, MDQC
ﬂagged 1 and 8. Further study of differential sensitivity to artifact
type will be warranted.
3.3 Large-scale applications
We applied this method to identify aberrant arrays from a pool of
507 microarrays from multiple clinical studies conducted by the
Immune Tolerance Network (ITN). This dataset was generated from
clinical human studies using peripheral blood samples, representing
a very different experimental setting from the MAQC study. There
is higher variability and little to no ability to perform technical
replicates due to cost and sample limitations. In the human
peripheral blood RNA microarray sample set, 18 microarrays, or
3.5%, were detected as outliers at α=0.01 (Fig. 2). We conﬁrmed
this approach to outlier detection by plotting the distribution
of arrays by individual QA indicator (Fig. 1) with the outlier
arrays highlighted in red. As shown, blue traces correspond to
arrays of high quality that fall within acceptable QA ranges as
previously described (GeneChip Expression Analysis Technical
Manual, www.affymetrix.com).Arrays that the approach ﬂagged as
outliers (Fig. 2) do not fall within the acceptable range for at least
one if not more of the QA parameters.
To demonstrate that our outlier detection method improves
the ability to determine meaningful changes in gene expression
(differential gene expression), we assessed the impact of our outliers
on gene expression estimates (absolute measures that are averaged
across all probes for a particular gene). Our assessment focused
on two trials where we expected differential expression based on
clinical phenotype or treatment regimen. In the ﬁrst case, we used a
set of 204 arrays from a ragweed allergy clinical trial. Our method
identiﬁed ﬁve outliers (Fig. 3A, shown in red and designated as
A–E) that are coincident with ﬁve points outside the major grouping
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Fig. 2. Parallel coordinate plots are a common way of visualizing multi-
variate data with different scales to facilitate detection of outliers. Applying
our QA approach, 18 of the 507 microarrays were ﬂagged as aberrant
(highlighted in red). As shown, our approach to QA has selected samples
as problematic where one or more indicators appear as an outlier based on
reductionofthedimensionalityofthedataviaPCAandapplyingasequential
Wilks’smultivariateoutliertestatanα =0.01.Ourapproachprovidesgreater
consistencyindesignatingproblematicarraysthroughastatisticalframework
that does not rely on arbitrary cutoffs for any individual indicator.
of samples on plots of PCA gene expression estimates. For outliers
ABC, this was due to poor (high) NUSE values, with only array
A having poor (low) percent present calls. Outliers D and E had
normal percent present calls and NUSE values, but poor GAPDH ,
actin (HSACO7) and RNA slope values.
Our second case study used a set of 42 microarrays from a kidney
transplant trial, in which three patient cohorts were compared. Here,
we detected three outliers using our method. These outliers also
correspond to arrays which fall outside the primary cluster on
PCA gene expression estimate plots (Fig. 3B Points F–H). In this
case, all three points falling out of the cluster had poor GAPDH,
actin (HSACO7) ratio, RNA slope, and NUSE values. Array F
had a poor percent present call, while G and H did not. While
the outlier arrays detected by our method correspond to arrays that
are outside the cluster of gene expression estimate PCA plots, our
approach provides improved discriminatory power in that it permits
discrimination of arrays that are outliers due to poor array quality
compared with those that are likely to reﬂect actual biological
variance.
3.4 Improvement of statistical power
The beneﬁt of excluding poor quality arrays in differential
expression analyses was further demonstrated through statistical
power calculations for these two clinical trials. Statistical power is
a major limiting factor in clinical microarray studies due to limited
sample size and lack of technical replicates.
Power calculations were performed, using PowerAtlas (Gadbury
et al., 2004), both with and without the two array outliers (Fig. 3A,
Points B and C) identiﬁed by our method. These two microarrays
correspond to data points that were collected to assess treatment
effect. The other three outliers in Fig. 3A addressed seasonal
effects of the study. Gadbury’s procedure ﬁts a two-component
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Fig. 3. PCA was applied to gene expression estimates for all genes in two
clinical trials. (A) The outlier detection approach described was applied to
204 arrays from a ragweed allergy study and identiﬁed ﬁve samples. These
microarrays are highlighted in red in the PCA 1 versus PCA 3 plot for
gene expression to show the relationship of outlier samples detected by
the system to actual gene expression estimates per array. Points A, B and
C have problematic NUSE values. Points D and E have abnormally high
GAPDH and HSAC07 ratios. The location of these arrays based on gene
expression PCA suggests that QA problems may contribute to deterioration
of overall expression. (B) A kidney transplant trial with 42 arrays where
three were detected as outliers. The three arrays are highlighted in red in
the PCA 1 versus PCA 2 gene expression plot. Points F, G and H have
abnormal NUSE, GAPDH and HSAC07 ratios. Again, the samples ﬂagged
by the QA approach appear to have gene expression estimates that differ
from the majority of other arrays. The arrayMvout package includes a map
fig3map from records in the ITN QA metrics matrix to samples labeled
A–H in these ﬁgures.
mixture of Beta variates to the distribution of P-values of gene-
speciﬁc differential expression tests. The two components of the
Beta model for P-values correspond to (i) the distribution of P
for non-differentially expressed genes (which will be uniform), and
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A
B
Fig. 4. Statistical power calculations. (A) Ragweed allergy study showing
improvedEDRuponremovalofarraysﬂaggedasPointsBandCinFigure3A
comparing two time points of interest. (B) Kidney transplant study showing
removal of two arrays ﬂagged as F and G in Figure 3B in a differential
expression comparison of two treatment cohorts.
(ii) the distribution of P for differentially expressed genes (which
will have mass predominantly near zero). Parametric bootstrapping
is then used in conjunction with the mixture model ﬁt to relate
the sample size of an experiment to the operating characteristics
of tests for differential expression. Gadbury deﬁnes the expected
discovery rate (EDR) as the expected proportion of genes that are
trulydifferentiallyexpressedthatwillbedeclaredtobedifferentially
expressed under a given design. If differential expression is present,
but tests of differential expression are impaired by the presence
of poor quality arrays, the P-values obtained will not be readily
resolved into two components, and power will be diminished. With
the arrays of low quality included, Gadbury’s estimate of the EDR
[with false discovery rate (FDR)=0.05] was 24.2% at a sample size
of10,whereastheEDRimprovedto73.3%forthesamesamplesize,
same FDR, through exclusion of the poor quality arrays (Fig. 4A).
Similarly, in our kidney transplantation case study, we compared
two of the three cohorts; each of these two cohorts had one outlier
(Fig. 3B, Points F and G). Power calculations with outlier arrays
both included and excluded showed that the EDR reached 14.1%
and 74.2%, respectively for a sample size of 30 (Fig. 4B).
4 CONCLUSION
While microarray post-hybridization quality indicators are readily
generated via standard output from analysis software packages,
cutoffs used to identify problematic arrays have typically been
subjective and arbitrary in nature. These indicators, by themselves,
do not always give the level of discrimination needed to distinguish
microarrays that are poor in quality.
We have proposed a three-step procedure for decision-making
about array quality.
• First, choose a collection of quantitative quality metrics.
For Affymetrix expression arrays, we have identiﬁed nine
metrics that appear to have reasonable utility, and for Illumina
expression arrays we use four metrics that are routinely
computed by open source software. These metrics can be
supplemented or restricted as desired by users.
• Second, compute the principal components re-expression of
the metrics and reduce the quality data to a modest number of
components. This step pursues parsimonious integration of the
various metrics and yields a multivariate quality representation
that should be reasonably approximated by the multivariate
Gaussian model.
• Third, apply calibrated parametric multivariate outlier
detection to a subset of the resulting quality principal
components. We propose Caroni and Prescott’s generalization
of Rosner’s GESD procedure, show that it has reasonable
speciﬁcity and sensitivity in several contexts, and indicate that
its use leads to increased inferential power in an important
clinical application.
Despite the attractive features identiﬁed above, prospective
users of statistical outlier labeling in microarray contexts need
to be cautious in their application of these methods. It is a
commonplace that the outliers are often the most interesting records
in any given database. Because we are studying outlyingness with
respect to average quality, the outlying arrays may be informative
about important events or discrepancies in the overall processing
workﬂow. It is also inevitable that the procedure described here
has several components conferring ﬂexibility, and, consequently,
manipulability. There is no basis at present for objective choice
of base quality metrics, for the choice of number of principal
components to use in reduction, or for the choice of null outlier
labeling rate α that will lead to greatest conﬁdence that arrays
labeled as outliers are truly aberrant and that unlabeled arrays
are of adequate quality. Thus, it is possible that two users may
obtain different decisions on identical data. We have designed
the ArrayOutliers tools so that they are reasonably self-
documenting, so that all applications can be audited.
There are various avenues along which the work described here
should be extended. First, by working with larger numbers of
arrays that have been independently classiﬁed into ‘acceptable’
and ‘unacceptable’ states, it should be possible to analyze the
contributions of different quality metrics to probabilities of class
membership. Second, when large numbers of arrays that are known
to be of good quality are available, the outlier detection process can
be supplemented by a ‘reference’database. Speciﬁcally, parametric
outlier testing can be conducted on the basis of a ﬁxed null mean
and covariance for quality features derived from a family of arrays
known to be of high quality. The arrayMvout package includes
matricesofqualitymeasuresfortheAffymetrixandIlluminaMAQC
contributions, which can support exploration of this reference-based
testing concept.
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